As of late February 2025, TauRx is still awaiting a response from the Medicines and Healthcare products Regulatory Agency (MHRA) on its application for hydromethylthionine mesylate (HMTM). HMTM is a tablet that could treat mild cognitive impairment and mild to moderate Alzheimer's disease.
Explanation
TauRx has submitted an application to the MHRA for HMTM.
The MHRA requested additional information from TauRx, and a response is due in late February 2025.
TauRx has also completed a Phase III clinical trial called LUCIDITY.
The LUCIDITY trial studied the effect of HMTM on patients with mild cognitive impairment and mild to moderate Alzheimer's disease.
The trial used brain scans, blood tests, and cognitive tests to measure how well HMTM might slow down Alzheimer's disease.
The results from earlier trials have shown that HMTM has a clinically meaningful therapeutic effect on cognitive decline and brain shrinkage.
TauRx is a global leader in tau-based research for treating Alzheimer's disease.